Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?

@article{Cutter2014DoesRS,
  title={Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?},
  author={Gary R. Cutter and Olaf St{\"u}ve},
  journal={Multiple sclerosis},
  year={2014},
  volume={20 10},
  pages={
          1304-5
        }
}
The use of natalizumab has likely been limited by its association with progressive multifocal leukoencephalopathy (PML), an infection caused by the human polyomavirus John Cunningham (JC). Three factors were recently identified that contribute to the overall risk of natalizumab-associated PML: (1) Positive serostatus for anti-JCV antibodies, (2) prior use of immunosuppressants, and (3) duration of natalizumab therapy. This risk stratification algorithm has not led to a reduction in the… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

Reassessing the risk of natalizumab-associated PML

  • Journal of NeuroVirology
  • 2016
VIEW 3 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-7 OF 7 REFERENCES

AntiJCV antibody index further defines PML risk in natalizumab-treated MS patients

T Plavina, G Bloomgren, S Richman
  • Annual Meeting of the Consortium of Multiple Sclerosis Centers,
  • 2013

AntiJCV antibody index further defines PML risk in natalizumab-treated MS patients

T Plavina, G Bloomgren, S Richman
  • Annual Meeting of the Consortium of Multiple Sclerosis Centers,
  • 2013